The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the ...

Asthma is a heterogeneous disease and can be classified by histologic background (eosinophilic or non-eosinophilic) or underlying mechanisms (allergic or non-allergic), with approximately half of ...

Eosinophilic patients had a median eosinophilic count of 440 cells/µL (interquartile range [IQR], 363-569) whereas non-eosinophilic patients had a median eosinophilic count of 90 cells/µL (IQR ...

Based on the Heaney algorithm, 69.6% were grade 3 and 20.8% were grade 2, both considered likely eosinophilic; 16.8% were grade 1, or less likely to be eosinophilic; and 5.9% were grade 0, or non ...

Mechanisms of non-T2 asthma, including neutrophilic inflammation and airway hyperresponsiveness. ... indicating a unique role in non-eosinophilic asthma pathology via a positive feedback loop.

--Avalo Therapeutics, Inc., announced that the first patient has been dosed in the company’ s Phase 2 PEAK trial evaluating AVTX-002 for the treatment of non-eosinophilic asthma.. "Dosing the ...

Company’s lead program is initially focused on the unmet need in eosinophilic and non-eosinophilic severe asthma patients with a Phase 1/1b study planned in 1H 2021 November 30, 2020 07:00 AM ...

With Vectura’s help, Kinaset will develop KN-002, an inhalable small molecule, to provide a treatment option for patients with severe non-eosinophilic asthma and offer patients with eosinophilic ...

Canadian patients with eosinophilic asthma can currently choose from 4 targeted monoclonal antibodies approved by Health Canada, including mepolizumab and reslizumab, which target IL-5, and ...